Mark S. Freedman

Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein

Kevin C. O’Connor, Katherine A. McLaughlin, Philip L. De Jager et al. · Nature Medicine · 2007 · 404 citations

Autoimmune Disease, Allergy, Autoantibody Production +12

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Krzysztof Selmaj, David K.B. Li, Hans-Peter Hartung et al. · The Lancet Neurology · 2013 · 230 citations

Relapsing-remitting Multiple Sclerosis, Disease Progression, Neurological Disorder +7

Peripheral blood γ‐δ T cells lyse fresh human brain—Derived oligodendrocytes

Mark S. Freedman, Theodora C.G. Ruijs, Liisa K. Selin et al. · Annals of Neurology · 1991 · 130 citations

NKG2D-Mediated Cytotoxicity toward Oligodendrocytes Suggests a Mechanism for Tissue Injury in Multiple Sclerosis

Philippe Saikali, Jack P. Antel, Jia Newcombe et al. · Journal of Neuroscience · 2007 · 101 citations · Full text